Department of Radiology, University of California Davis, Sacramento, CA, USA.
Department of Neurological Surgery, University of California Davis, Sacramento, CA, USA.
Interv Neuroradiol. 2021 Feb;27(1):75-80. doi: 10.1177/1591019920959534. Epub 2020 Sep 23.
Aneurysmal subarachnoid hemorrhage (SAH) is the most common cause of nontraumatic SAH. Current guidelines generally recommend observation for unruptured intracranial aneurysms smaller than 7 mm, for those are considered at low risk for spontaneous rupture according to available scoring systems.
We observed a tendency for SAH in small intracranial aneurysms in patients who are methamphetamine users. A retrospective, single center study to characterize the size and location of ruptured and unruptured intracranial aneurysms in methamphetamine users was performed.
Clinical characteristics and patient data were collected via retrospective chart review of patients with intracranial aneurysms and a history of methamphetamine use with a specific focus on aneurysm size and location.
A total of 62 patients were identified with at least one intracranial aneurysm and a history of methamphetamine use, yielding 73 intracranial aneurysms (n = 73). The mean largest diameter of unruptured aneurysms (n = 44) was 5.1 mm (median 4.5, SD 2.5 mm), smaller than for ruptured aneurysms (n = 29) with a mean diameter of 6.3 mm (median 5.5, SD 2.5 mm). Aneurysms measuring less than 7 mm presented with SAH in 36.5%. With regard to location, 28% (n = 42) of anterior circulation aneurysms less than 7 mm presented with rupture, in contrast to 70% (n = 10) of posterior circulation aneurysms which were found to be ruptured.
Methamphetamine use may be considered a significant risk factor for aneurysmal SAH at a smaller aneurysm size than for other patients. These patients may benefit from a lower threshold for intervention and/or aggressive imaging and clinical follow-up.
蛛网膜下腔出血(SAH)是最常见的非创伤性蛛网膜下腔出血的原因。目前的指南通常建议对小于 7mm 的未破裂颅内动脉瘤进行观察,因为根据现有评分系统,这些动脉瘤被认为破裂的风险较低。
我们观察到在使用甲基苯丙胺的患者中,小的颅内动脉瘤有发生 SAH 的趋势。进行了一项回顾性、单中心研究,以描述使用甲基苯丙胺的患者中破裂和未破裂颅内动脉瘤的大小和位置。
通过回顾性病历审查收集颅内动脉瘤和使用甲基苯丙胺病史的患者的临床特征和患者数据,特别关注动脉瘤的大小和位置。
共确定了 62 名至少有一个颅内动脉瘤和使用甲基苯丙胺病史的患者,共 73 个颅内动脉瘤(n=73)。未破裂动脉瘤(n=44)的最大直径平均值为 5.1mm(中位数 4.5,标准差 2.5mm),小于破裂动脉瘤(n=29)的最大直径平均值 6.3mm(中位数 5.5,标准差 2.5mm)。直径小于 7mm 的动脉瘤中有 36.5%出现 SAH。就位置而言,28%(n=42)的小于 7mm 的前循环动脉瘤发生破裂,而破裂的后循环动脉瘤占 70%(n=10)。
与其他患者相比,使用甲基苯丙胺可能被认为是较小动脉瘤发生动脉瘤性 SAH 的一个重要危险因素。这些患者可能受益于介入和/或积极的影像学和临床随访的门槛降低。